Full-Time

Senior Manager

Instructional Design and Labeling Operations

Updated on 8/1/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$148.7k - $201.2k/yr

+ Annual bonus + Stock-based long-term incentives

H1B Sponsorship Available

Thousand Oaks, CA, USA

Hybrid

Hybrid work arrangement with flex commuter expectations.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Six Sigma

Get referred to Amgen

See people who can refer or advise you

Requirements
  • Doctorate degree and 2 years of regulated labeling, medical device, combination product, instructional design, Human Factors, design operations, process improvement, product development, quality, or related experience; or master's degree and 6 years of such experience; or bachelor's degree and 8 years of such experience; or associate's degree and 10 years of such experience; or high school diploma or GED and 12 years of such experience.
  • At least 2 years of experience directly managing people and/or leadership experience leading teams, projects, programs, or directing the allocation of resources.
  • The role requires people leadership, process ownership, stakeholder management, and regulated medical product experience.
  • The role requires leadership across labeling, artwork, Human Factors study support, source text alignment, documentation, review cycles, vendor coordination, and Health Authority submission readiness.
Responsibilities
  • Lead, coach, and develop a team of Instructional Design Engineers.
  • Clarify role expectations, support development plans, create growth opportunities, and help team members build differentiated career paths.
  • Build a high-performing team culture grounded in accountability, collaboration, learning, quality, operational discipline, and customer focus.
  • Manage team priorities, workload, capacity, onboarding, performance, development, and resource allocation.
  • Provide oversight of external workers and contractors, including onboarding, work assignment, deliverable expectations, execution quality, and integration into team workflows.
  • Lead the Instructional Design and Labeling Operations function within Customer Experience and Design.
  • Translate portfolio needs, Human Factors milestones, labeling deliverables, study timelines, submission needs, and business priorities into executable team plans.
  • Establish mechanisms to monitor workload, workflow health, quality trends, cycle times, risks, rework drivers, and delivery commitments.
  • Strengthen the operating model for Instructional Design and Labeling Operations, including role clarity, decision rights, intake, prioritization, escalation, metrics, and cross-functional handoffs.
  • Ensure the team's work supports broader Customer Experience objectives, including improved patient learning materials, usability, complaint reduction, and customer experience outcomes.
  • Lead process improvement efforts across the Instructions for Use and Native Artwork Files lifecycle, including strategy, creation, revision, review cycles, Human Factors study support, source text alignment, submission support, vendor coordination, and launch readiness activities.
  • Develop, maintain, and improve templates, checklists, standards, process maps, training materials, metrics, and review expectations.
  • Identify and resolve process gaps, handoff inefficiencies, documentation risks, role clarity issues, recurring workflow pain points, and compliance vulnerabilities.
  • Provide leadership oversight for development and revision of Instructions for Use, instructional artwork, illustrations, Native Artwork Files, study stimuli, and related deliverables.
  • Ensure deliverables address user needs, usability principles, labeling requirements, regulatory expectations, documentation traceability, and quality standards.
  • Oversee Native Artwork Files strategy, artwork creation, review cycles, source text alignment, print readiness, study stimuli preparation, vendor coordination, and submission readiness.
  • Ensure appropriate quality checks, review discipline, documentation, and inspection practices are in place before deliverables progress to formal review, study use, or submission.
  • Support issue resolution and decision-making when design, usability, labeling, regulatory, packaging, artwork, quality, or operational considerations conflict.
  • Build partnerships with Human Factors, Regulatory Labeling, Packaging Engineering, Artwork Center, Systems Engineering, Quality, Final Product Teams, vendors, and other partners.
  • Represent Instructional Design and Labeling Operations in portfolio, program, governance, and process discussions.
  • Communicate priorities, risks, decisions, and tradeoffs clearly to senior leaders and cross-functional stakeholders.
  • Influence across matrix teams to drive alignment, remove barriers, and maintain momentum.
  • Manage vendor and contractor relationships to support execution, capacity, quality, specialized capability, print readiness, study support, and process reliability.
  • Ensure vendors and external partners understand applicable expectations, timelines, deliverable standards, documentation needs, and escalation pathways.
  • Ensure activities are performed and documented in accordance with applicable procedures, standards, and regulatory expectations.
  • Promote documentation practices that provide traceability of inputs, decisions, reviews, revisions, approvals, study support activities, and submission-related deliverables.
  • Support audit readiness, inspection readiness, and responses to Health Authority questions or feedback related to deliverables.
  • Drive quality ownership, right-first-time execution, and continuous learning from errors, rework, study outcomes, stakeholder feedback, and process metrics.
Desired Qualifications
  • Demonstrated people leadership experience, including coaching, performance management, career development, workload management, and building high-performing teams.
  • Experience leading full-time employees, external workers, contractors, vendors, or matrixed contributors in a regulated or quality-sensitive environment.
  • Experience in regulated medical product labeling, artwork, packaging, Human Factors, medical device, pharmaceutical, biotechnology, combination product, quality, or design operations.
  • Combination product experience; broader regulated medical space labeling or artwork experience may be suitable.
  • Experience improving processes, implementing standard operating procedures, developing templates and checklists, defining role clarity, and scaling functional operations.
  • Experience owning or governing controlled procedures, including implementation, adherence, training, inspection readiness, and continuous improvement.
  • Knowledge of Instructions for Use, instructional materials, labeling and artwork development, Human Factors study materials, Health Authority submission support, or regulated document workflows.
  • Experience with document management systems, review workflows, source text and artwork alignment, traceability, and audit-ready documentation.
  • Vendor management experience, including defining expectations, managing deliverables, monitoring performance, and resolving quality or timeline issues.
  • Strong cross-functional leadership and influencing skills with the ability to align stakeholders across technical, regulatory, quality, operational, and design perspectives.
  • Ability to manage multiple priorities, identify risks, escalate appropriately, and drive decisions in a matrixed environment.
  • Strong written, verbal, facilitation, and executive communication skills.
  • Demonstrated ability to translate customer, patient, user, and business needs into practical operational improvements.
  • Lean, Six Sigma, process excellence, change management, or operational excellence experience.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • A broad pipeline targets heart disease, obesity, rare disease, inflammation, and cancer.
  • Global reach across roughly 100 countries supports scale and diversification.
  • Legacy cash flows from mature biologics fund new medicine development.

What critics are saying

  • Enbrel faces pricing pressure after Colorado's 70% price-cap challenge.
  • Recent Corlanor and Sensipar recalls expose manufacturing and quality-control weaknesses.
  • Biosimilar competition threatens mature biologics and compresses future margins.

What makes Amgen unique

  • Amgen combines biologics discovery, manufacturing, and commercialization under one integrated platform.
  • Its portfolio spans oncology, cardiovascular, inflammation, bone health, and rare disease.
  • Human genetics and biology guide its drug discovery strategy.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.